Publicaciones en las que colabora con Álvaro Mena de Cea (13)

2019

  1. Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis c virus infected patients. Results in real clinical practice

    Revista Espanola de Quimioterapia, Vol. 32, Núm. 2, pp. 137-144

2017

  1. Characterization of chronic HCV infection in Northwest Spain: Impact of the treatment strategic plan of the Spanish National Health Service on HCV cure

    Journal of Medical Virology, Vol. 89, Núm. 7, pp. 1304-1308

  2. Increased incidence of cancer observed in HIV/hepatitis C virus-coinfected patients versus HIV-monoinfected

    AIDS, Vol. 31, Núm. 8, pp. 1099-1107

  3. Plasma mitochondrial DNA levels are inversely associated with HIV-RNA levels and directly with CD4 counts: Potential role as a biomarker of HIV replication

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 11, pp. 3159-3162

  4. Tendencia de las hospitalizaciones, reingresos y mortalidad intrahospitalaria en los pacientes infectados por VIH entre 1993-2013: impacto de la coinfección por el virus de la hepatitis C

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 35, Núm. 1, pp. 20-26

2016

  1. Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART?

    Journal of Antimicrobial Chemotherapy, Vol. 71, Núm. 4, pp. 1051-1055

  2. European mitochondrial haplogroups impact on liver fibrosis progression among HCV and HIV/HCV-coinfected patients from Northwest Spain

    Journal of Acquired Immune Deficiency Syndromes, Vol. 73, Núm. 2, pp. 149-153

  3. Long-term clinical experience with darunavir (2007–2015) in a large cohort of HIV-infected patients in Spain

    Journal of Medical Virology, Vol. 88, Núm. 12, pp. 2125-2131

2015

  1. Trends on epidemiological, virological, and clinical features among newly diagnosed HIV-1 persons in Northwest Spain over the last 10 years

    Journal of Medical Virology, Vol. 87, Núm. 8, pp. 1319-1326

2014

  1. High prevalence of subtype F in newly diagnosed HIV-1 persons in northwest Spain and evidence for impaired treatment response

    AIDS, Vol. 28, Núm. 12, pp. 1837-1840

  2. Seroprevalence of HCV and HIV infections by year of birth in Spain: Impact of US CDC and USPSTF recommendations for HCV and HIV testing

    PLoS ONE, Vol. 9, Núm. 12

2010

  1. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C

    Journal of Antimicrobial Chemotherapy, Vol. 65, Núm. 3, pp. 543-547

  2. Simplification from protease inhibitors to once-or twice-daily raltegravir: The ODIS trial

    HIV Clinical Trials, Vol. 11, Núm. 4, pp. 197-204